Jensen-Munroe relapsed in 2023 and was told unfunded, $220,000-a-year drug daratumumab was her “best option”. Unable to afford that, last year she took the second option of a stem cell transplant.

Suggested remit: To appraise the clinical and cost effectiveness of daratumumab with bortezomib, lenalidomide and dexamethasone within its marketing authorisation for untreated multiple myeloma when ...

Morningstar brands and products Company Portfolio ...